venous thrombosis

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

antithrombotics

not classified
EINSTEIN CHOICE (10mg), 2017rivaroxaban 10mgaspirinNCT02064439 -
DURAC II, 1997VKAcontrol -
WODIT DVT, 2001VKAcontrol -
WODIT PE, 2003VKAcontrol -
AUREC FVII, 2009VKAcontrol -
DACUS (Siragusa), 2008VKAcontrolNCT00438230 -
PROLONG (Palarati), 2006VKAcontrolNCT00264277 -
DDOAT2006 ongoing VKAcontrolNCT00895505 ongoing
Vitotec, 2009warfarincontrol -
ELATE, 2003warfarinlow intensity warfarin -
AMPLIFY EXT 2.5mg, 2013apixaban 2.5mgplacebo -
AMPLIFY EXT 5mg, 2013apixaban 5mgplacebo -
WARFASA, 2012aspirinplacebo -
ASPIRE, 2012aspirinplacebo -
RESONATE, 2013dabigatranplacebo -
Van Gogh, 2007idraparinuxplaceboNCT00071279 -
PREVENT, 2003low-intensity warfarinplacebo -
EISNTEIN EXT, 2010rivaroxaban 20mgplacebo -
PADIS-PE (Couturaud), 2015VKAplaceboNCT00740883 -
LAFIT, 1999warfarinplacebo -
Levine, 1995warfarinplacebo -
THRIVE 3, 2003ximelagatranplacebo -
REMEDY, 2013dabigatranwarfarin -
EINSTEIN CHOICE (20mg), 2017rivaroxaban 20mgaspirinNCT02064439 -
Boccalon, 2000LMWH at homeUFH in hospitalnegative
Chong, 2005LMWH at homeUFH in hospitalsuggesting
Daskalopoulos, 2005LMWH at homeUFH in hospitalnegative
Koopman, 1996LMWH at homeUFH in hospitalnegative
Levine, 1996LMWH at homeUFH in hospitalnegative
Ramacciotti, 2004LMWH at homeUFH in hospitalnegative
Faivre et al , 1988Minoctoparineunfractionated heparinnegative
apixaban
AMPLIFY-EXT 2.5mg, 2012apixaban 2.5mgdiscontinuationNCT00633893suggesting
AMPLIFY-EXT 5mg, 2012apixaban 5mgdiscontinuationNCT00633893suggesting
Botticelli DVT, 2008apixaban (without LMWH)LMWH/VKANCT00252005Exploratory -
AMPLIFY, 2013apixaban (without LMWH)LMWH/VKA DOAC without heparin NCT00643201Low risk of bias suggesting
aspirin
WARFASA, 2012aspirindiscontinuationNCT00222677suggesting
ASPIRE, 2012aspirindiscontinuationACTRN12605000004662suggesting
Bemiparin
Kakkar, 2003BemiparinwarfarinRisk of bias negative
dabigatran
RE-MEDY, 2011dabigatranwarfarinNCT00329238Low risk of bias suggesting
RE-SONATE, 2011dabigatrandiscontinuationNCT00558259suggesting
RE-COVER, 2009heparin/dabigatranheparin/VKA heparin - DOAC NCT00291330Low risk of bias suggesting
dalteparin
Lee, 2003extended dalteparinstandard treatmentsuggesting
Das, 1996DalteparinwarfarinRisk of bias negative
Lee, 2003DalteparinwarfarinRisk of bias suggesting
Holmström, 1992once daily dalteparintwice daily dalteparinnegative
Partsch, 1996once daily dalteparintwice daily dalteparinnegative
Bratt et al , 1985Dalteparinunfractionated heparinnegative
Holm et al , 1986Dalteparinunfractionated heparinnegative
Bratt et al, 1990Dalteparinunfractionated heparinnegative
Lindmarker et al , 1993Dalteparinunfractionated heparinnegative
enoxaparin
Veiga, 2000EnoxaparinacenocoumarolRisk of bias negative
González-Fajardo, 2008EnoxaparincoumarinRisk of bias -
Cesarone, 2003extended enoxaparinstandard treatmentnegative
Deitcher, 2006extended enoxaparinstandard treatmentnegative
Meyer, 2002extended enoxaparinstandard treatmentnegative
Pini, 1994EnoxaparinwarfarinRisk of bias negative
Gonzalez-Fajardo, 1999EnoxaparinwarfarinRisk of bias suggesting
Meyer, 2002EnoxaparinwarfarinRisk of bias negative
Deitcher, 2003EnoxaparinwarfarinRisk of bias negative
Merli, 2001once daily enoxaparintwice daily enoxaparinnegative
Merli (once daily vs UFH), 2001once daily enoxaparinUFHLow risk of bias negative
Simonneau et al , 1993Enoxaparinunfractionated heparinnegative
fondaparinux
MATISSE, 2004fondaparinuxenoxaparinLow risk of bias negative
MATISSE PE, 2003fondaparinuxheparinRisk of bias negative
heparin
Ott importé, 1998heparin+warfarinplacebonegative
Krahenbuhl, 1979subcutaneous heparinintravenous heparin -
Bentley, 1980subcutaneous heparinintravenous heparinsuggesting
Andersson, 1982subcutaneous heparinintravenous heparin -
Hull, 1986subcutaneous heparinintravenous heparinnegative
Doyle, 1987subcutaneous heparinintravenous heparinnegative
Walker, 1987subcutaneous heparinintravenous heparinsuggesting
Lopaciuksubcutaneous heparinintravenous heparinnegative
Pini, 1990subcutaneous heparinintravenous heparinnegative
Nielsen importé, 1994heparin+phenprocoumonphenylbutazone -
idraparinux
Van Gogh (subgroup), 2011idraparinuxstandard treatmentExploratory negative
VanGogh DVT, 2007idraparinux (without heparin)heparin/VKANCT00067093Exploratory suggesting
VanGogh PE, 2007idraparinux (without heparin)heparin/VKANCT00062803Risk of bias negative
logiparin
Siegbahn, 1989once daily logiparintwice daily logiparinnegative
nadroparin
Lopaciuk, 1999NadroparinacenocoumarolRisk of bias negative
Lopez-Beret, 2001NadroparinacenocoumarolRisk of bias negative
Lopez Beret, 2001extended nadroparinstandard treatmentnegative
Charbonnier, 1998once daily nadroparintwice daily nadroparinnegative
Collaborative European Multicentre, 1991Nadroparinunfractionated heparinnegative
Prandoni et al , 1992Nadroparinunfractionated heparinsuggesting
Lopaciuk et al , 1992Nadroparinunfractionated heparinnegative
rivaroxaban
EINSTEIN-extension, 2009rivaroxabandiscontinuationNCT00439725Low risk of bias suggesting
Einstein-DVT Dose-Ranging Study, 2008rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010rivaroxaban (without LMWH)LMWH/VKA DOAC without heparin NCT00440193Low risk of bias suggesting
Einstein-PE Evaluation, 2012rivaroxaban (without LMWH)LMWH/VKANCT00439777Risk of bias -
rosuvastatin
VanGogh extension, 2007idraparinuxdiscontinuationNCT00071279suggesting
tinzaparin
Romera, 2009TinzaparinacenocoumarolRisk of bias suggesting
Hull, 2006extended tinzaparinstandard treatmentnegative
Hull, 2002TinzaparinwarfarinRisk of bias negative
Hull et al , 1992Tinzaparinunfractionated heparinsuggesting
warfarin
Schulman, 19956 months1.5 monthssuggesting
Pinede, 20013-6 months1.5-3 monthsnegative
Wells (subgroup), 2005tinzaparindalteparinnegative
Levine, 1995warfarindiscontinuationsuggesting
LAFIT (Kearon), 1999warfarindiscontinuationsuggesting
Agnelli, 2001warfarindiscontinuationnegative
Agnelli, 2003warfarindiscontinuationnegative
PREVENT (Ridker), 2003warfarindiscontinuationsuggesting
ELAET (Kearon), 2004warfarindiscontinuationnegative
DURAC (Schulman), 1997warfarindiscontinuationsuggesting
PROLONG (Palareti), 2006warfarindiscontinuationNCT00264277suggesting
ximelagatran
THRIVE III, 2003ximelagatrandiscontinuationLow risk of bias suggesting
Schulman (subgroup), 2003ximelagatranplacebo -
Fiessinger , 2005ximelagatranLMWH/VKA -
THRIVE I, 2003ximelagatran (without LMWH)LMWH/VKA -

caval filter

caval filter
PREPIC, 1998caval filterno filterLow risk of bias suggesting

direct factor Xa inhibitors

ximelagatran
THRIVE III, 2003ximelagatrandiscontinuationLow risk of bias suggesting

direct oral anticoagulant (DAO)

not classified
EINSTEIN CHOICE (20mg), 2017rivaroxaban 20mgaspirinNCT02064439 -
apixaban
AMPLIFY-EXT 2.5mg, 2012apixaban 2.5mgdiscontinuationNCT00633893suggesting
AMPLIFY-EXT 5mg, 2012apixaban 5mgdiscontinuationNCT00633893suggesting
Botticelli DVT, 2008apixaban (without LMWH)LMWH/VKANCT00252005Exploratory -
AMPLIFY, 2013apixaban (without LMWH)LMWH/VKA DOAC without heparin NCT00643201Low risk of bias suggesting
dabigatran
RE-MEDY, 2011dabigatranwarfarinNCT00329238Low risk of bias suggesting
RE-SONATE, 2011dabigatrandiscontinuationNCT00558259suggesting
RE-COVER, 2009heparin/dabigatranheparin/VKA heparin - DOAC NCT00291330Low risk of bias suggesting
RE-COVER II, 2011heparin/dabigatranheparin/VKA heparin - DOAC NCT00680186suggesting
edoxaban
Edoxaban Hokusai VTE, 2013heparin/edoxabanheparin/VKA heparin - DOAC NCT00986154Low risk of bias suggesting
rivaroxaban
EINSTEIN-extension, 2009rivaroxabandiscontinuationNCT00439725Low risk of bias suggesting
Einstein-DVT Dose-Ranging Study, 2008rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010rivaroxaban (without LMWH)LMWH/VKA DOAC without heparin NCT00440193Low risk of bias suggesting
Einstein-PE Evaluation, 2012rivaroxaban (without LMWH)LMWH/VKANCT00439777Risk of bias -
rosuvastatin
VanGogh extension, 2007idraparinuxdiscontinuationNCT00071279suggesting
ximelagatran
THRIVE III, 2003ximelagatrandiscontinuationLow risk of bias suggesting
THRIVE I, 2003ximelagatran (without LMWH)LMWH/VKA -

fibrinolysis

not classified
Kakkar (arvin), 1969arvinno fibrinolysis -
heparin
Schweizer tPA, 1998tPA+heparinno fibrinolysisnegative
streptokinase
Arneson, 1978streptokinaseno fibrinolysisnegative
Common, 1976streptokinaseno fibrinolysisnegative
Elsharawy, 2002streptokinaseno fibrinolysisnegative
Schulman, 1986streptokinaseno fibrinolysisnegative
Tsapogas, 1973streptokinaseno fibrinolysisnegative
Kakkar (streptokinase), 1969streptokinaseno fibrinolysisnegative
Schweizer (systemic SK), 2000streptokinaseno fibrinolysis -
t-pa
Goldhaber (tPA alone), 1990tPAno fibrinolysisnegative
Schweizer (local tPA), 2000tPAno fibrinolysis -
Turpie, 1990tPAno fibrinolysisnegative
Verhaeghe (high dose), 1989tPAno fibrinolysis -
Goldhaber (tPA+heparin), 1990tPAno fibrinolysis -
Verhaeghe (low dose), 1989tPAno fibrinolysis -
urokinase
Kiil, 1981urokinaseno fibrinolysisnegative
Schweizer (urokinase), 1998urokinaseno fibrinolysisnegative
Schweizer (local urokinase), 2000urokinaseno fibrinolysis -
Schweizer (systemic urokinase), 2000urokinaseno fibrinolysis -

heparin (UFH or LMWH)

not classified
Boccalon, 2000LMWH at homeUFH in hospitalnegative
Chong, 2005LMWH at homeUFH in hospitalsuggesting
Daskalopoulos, 2005LMWH at homeUFH in hospitalnegative
Koopman, 1996LMWH at homeUFH in hospitalnegative
Levine, 1996LMWH at homeUFH in hospitalnegative
Ramacciotti, 2004LMWH at homeUFH in hospitalnegative
Faivre et al , 1988Minoctoparineunfractionated heparinnegative
Bemiparin
Kakkar, 2003BemiparinwarfarinRisk of bias negative
dalteparin
Das, 1996DalteparinwarfarinRisk of bias negative
Lee, 2003DalteparinwarfarinRisk of bias suggesting
Holmström, 1992once daily dalteparintwice daily dalteparinnegative
Partsch, 1996once daily dalteparintwice daily dalteparinnegative
Bratt et al , 1985Dalteparinunfractionated heparinnegative
Holm et al , 1986Dalteparinunfractionated heparinnegative
Bratt et al, 1990Dalteparinunfractionated heparinnegative
Lindmarker et al , 1993Dalteparinunfractionated heparinnegative
enoxaparin
Veiga, 2000EnoxaparinacenocoumarolRisk of bias negative
González-Fajardo, 2008EnoxaparincoumarinRisk of bias -
Pini, 1994EnoxaparinwarfarinRisk of bias negative
Gonzalez-Fajardo, 1999EnoxaparinwarfarinRisk of bias suggesting
Meyer, 2002EnoxaparinwarfarinRisk of bias negative
Deitcher, 2003EnoxaparinwarfarinRisk of bias negative
Merli, 2001once daily enoxaparintwice daily enoxaparinnegative
Merli (once daily vs UFH), 2001once daily enoxaparinUFHLow risk of bias negative
Simonneau et al , 1993Enoxaparinunfractionated heparinnegative
heparin
Krahenbuhl, 1979subcutaneous heparinintravenous heparin -
Bentley, 1980subcutaneous heparinintravenous heparinsuggesting
Andersson, 1982subcutaneous heparinintravenous heparin -
Hull, 1986subcutaneous heparinintravenous heparinnegative
Doyle, 1987subcutaneous heparinintravenous heparinnegative
Walker, 1987subcutaneous heparinintravenous heparinsuggesting
Lopaciuksubcutaneous heparinintravenous heparinnegative
Pini, 1990subcutaneous heparinintravenous heparinnegative
logiparin
Siegbahn, 1989once daily logiparintwice daily logiparinnegative
nadroparin
Lopaciuk, 1999NadroparinacenocoumarolRisk of bias negative
Lopez-Beret, 2001NadroparinacenocoumarolRisk of bias negative
Charbonnier, 1998once daily nadroparintwice daily nadroparinnegative
Collaborative European Multicentre, 1991Nadroparinunfractionated heparinnegative
Prandoni et al , 1992Nadroparinunfractionated heparinsuggesting
Lopaciuk et al , 1992Nadroparinunfractionated heparinnegative
tinzaparin
Romera, 2009TinzaparinacenocoumarolRisk of bias suggesting
Hull, 2002TinzaparinwarfarinRisk of bias negative
Hull et al , 1992Tinzaparinunfractionated heparinsuggesting
warfarin
Schulman, 19956 months1.5 monthssuggesting
Pinede, 20013-6 months1.5-3 monthsnegative
Levine, 1995warfarindiscontinuationsuggesting
LAFIT (Kearon), 1999warfarindiscontinuationsuggesting
Agnelli, 2001warfarindiscontinuationnegative
Agnelli, 2003warfarindiscontinuationnegative
PREVENT (Ridker), 2003warfarindiscontinuationsuggesting
ELAET (Kearon), 2004warfarindiscontinuationnegative
DURAC (Schulman), 1997warfarindiscontinuationsuggesting

LMWH

not classified
Boccalon, 2000LMWH at homeUFH in hospitalnegative
Chong, 2005LMWH at homeUFH in hospitalsuggesting
Daskalopoulos, 2005LMWH at homeUFH in hospitalnegative
Koopman, 1996LMWH at homeUFH in hospitalnegative
Levine, 1996LMWH at homeUFH in hospitalnegative
Ramacciotti, 2004LMWH at homeUFH in hospitalnegative
Faivre et al , 1988Minoctoparineunfractionated heparinnegative
Bemiparin
Kakkar, 2003BemiparinwarfarinRisk of bias negative
dalteparin
Das, 1996DalteparinwarfarinRisk of bias negative
Lee, 2003DalteparinwarfarinRisk of bias suggesting
Holmström, 1992once daily dalteparintwice daily dalteparinnegative
Partsch, 1996once daily dalteparintwice daily dalteparinnegative
Bratt et al , 1985Dalteparinunfractionated heparinnegative
Holm et al , 1986Dalteparinunfractionated heparinnegative
Bratt et al, 1990Dalteparinunfractionated heparinnegative
Lindmarker et al , 1993Dalteparinunfractionated heparinnegative
enoxaparin
Veiga, 2000EnoxaparinacenocoumarolRisk of bias negative
González-Fajardo, 2008EnoxaparincoumarinRisk of bias -
Pini, 1994EnoxaparinwarfarinRisk of bias negative
Gonzalez-Fajardo, 1999EnoxaparinwarfarinRisk of bias suggesting
Meyer, 2002EnoxaparinwarfarinRisk of bias negative
Deitcher, 2003EnoxaparinwarfarinRisk of bias negative
Merli, 2001once daily enoxaparintwice daily enoxaparinnegative
Merli (once daily vs UFH), 2001once daily enoxaparinUFHLow risk of bias negative
Simonneau et al , 1993Enoxaparinunfractionated heparinnegative
logiparin
Siegbahn, 1989once daily logiparintwice daily logiparinnegative
nadroparin
Lopaciuk, 1999NadroparinacenocoumarolRisk of bias negative
Lopez-Beret, 2001NadroparinacenocoumarolRisk of bias negative
Charbonnier, 1998once daily nadroparintwice daily nadroparinnegative
Collaborative European Multicentre, 1991Nadroparinunfractionated heparinnegative
Prandoni et al , 1992Nadroparinunfractionated heparinsuggesting
Lopaciuk et al , 1992Nadroparinunfractionated heparinnegative
tinzaparin
Romera, 2009TinzaparinacenocoumarolRisk of bias suggesting
Hull, 2002TinzaparinwarfarinRisk of bias negative
Hull et al , 1992Tinzaparinunfractionated heparinsuggesting

UFH

heparin
Krahenbuhl, 1979subcutaneous heparinintravenous heparin -
Bentley, 1980subcutaneous heparinintravenous heparinsuggesting
Andersson, 1982subcutaneous heparinintravenous heparin -
Hull, 1986subcutaneous heparinintravenous heparinnegative
Doyle, 1987subcutaneous heparinintravenous heparinnegative
Walker, 1987subcutaneous heparinintravenous heparinsuggesting
Lopaciuksubcutaneous heparinintravenous heparinnegative
Pini, 1990subcutaneous heparinintravenous heparinnegative